- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Study Compares Adjuvant Radiotherapy With Observation in Low-Risk DCIS
The study, published in the Journal of Clinical Oncology concluded that the failure rate was low with observation but was decreased significantly with the addition of radiotherapy.
Two-group randomized controlled trials often have a winner and a loser. But sometimes the results are "win—win." This appears to be the case with the first-ever randomized trial that compares adjuvant radiotherapy (RT) with observation in women with "good-risk" ductal carcinoma in situ (DCIS).
The investigators, led by Beryl McCormick, MD, from the Memorial Sloan Kettering Cancer Center in New York City, expect that their data will be used to endorse both treatment choices in the setting of good (or low-risk) DCIS. They say the trial results both "support" the decision to omit RT and "confirm" that RT offers "significant benefit in further reducing in-breast recurrence."
The study was published online January 20 in the Journal of Clinical Oncology.
Read the report on Medscape: http://bit.ly/1u3lu0U
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
